Autres langues Orexo AB

Actions

ORX

SE0000736415

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:36 03/05/2024			Varia. 5j.	Varia. 1 janv.
18,24 ^SEK	+6,05 %		+10,28 %	+17,98 %

17/04	Orexo étend la protection par brevet de son produit en poudre d'épinéphrine nasale OX640 aux États-Unis	CI
02/04	La société suédoise Orexo s'apprête à rembourser par anticipation ses obligations à échéance 2025	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Orexo : Invitation to presentation of Orexo´s Q1 2024 Interim Report	02/05
Report from Orexo AB's annual general meeting, 26 April 2024	26/04
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	17/04
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	17/04
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	17/04
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	02/04
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	02/04
Orexo publishes the Annual and Sustainability Report for 2023	28/03
Orexo AB Announces Board Resignations	22/03
Correction: Notice of Annual General Meeting of Orexo	15/03
Notice of Annual General Meeting of Orexo	15/03
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	14/03
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	13/03
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	13/03
Orexo Plans SEK500 Million New Social Bond Issuance, Tender Offer	08/03
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	08/03
Orexo strengthens its sustainability work by establishing a social financing framework	08/03
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	12/02
Orexo and Sobi agree to advance feasibility study with AmorphOX	12/02
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	12/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Orexo AB

Actions

ORX

SE0000736415

Autres langues

Filtres